Clinical Pharmacology in Psychiatry: Neuroleptic and Antidepressant Research

Front Matter....Pages i-xviii
Front Matter....Pages 1-1
Evaluation of existing methods for quantitation of neuroleptics in relation to clinical use....Pages 3-9
Alternative Approaches....Pages 11-17
Radioimmunoassay of tricyclic antidepressants....Pages 19-25
Biological assay systems for tricyclic antidepressants....Pages 27-32
Front Matter....Pages 33-33
Review on neuroleptic receptors: specificity and multiplicity of in vitro binding related to pharmacological activity....Pages 35-62
High affinity 3H-imipramine binding: a new tool in biological psychiatry....Pages 63-77
A radioreceptor assay for neuroleptic drugs....Pages 79-104
Radioreceptor binding technique as aid in treatment with neuroleptics....Pages 105-109
Preliminary assessment of a calf caudate radioreceptor assay for the estimation of neuroleptic drugs in plasma: comparison with other techniques....Pages 111-121
Front Matter....Pages 123-123
Active metabolites of phenothiazine drugs....Pages 125-137
Active metabolites of tricyclic antidepressants....Pages 139-153
Preliminary studies on the effect of dothiepin and its metabolites on serotonin uptake by human blood platelets in vitro....Pages 155-160
Active metabolites of antidepressants: novel aspects of hydroxylation and demethylation in man....Pages 161-169
Front Matter....Pages 171-171
Plasma and tissue binding of psychotropic drugs....Pages 173-176
Protein binding and monitoring of psychotherapeutic drugs in plasma....Pages 177-190
Plasma protein binding of haloperidol: influence of age and disease states....Pages 191-196
Front Matter....Pages 197-197
Clinical significance of neuroleptic plasma level monitoring....Pages 199-209
The clinical significance of measuring perphenazine in plasma during oral antipsychotic treatment....Pages 211-216
Serum haloperidol determinations and their contribution to the treatment of schizophrenia....Pages 217-225
Haloperidol plasma levels in relation to antimanic effect....Pages 227-232
Front Matter....Pages 197-197
Haloperidol plasma levels and clinical response in schizophrenia....Pages 233-237
Pharmacokinetics and plasma level/effect relationships of tricyclic antidepressants: an update....Pages 241-251
Pharmacokinetics of high clearance drugs and their metabolites....Pages 253-262
Prediction of plasma levels and clinical response in depression....Pages 263-271
Kinetic aspects of nortriptyline dose regimen....Pages 273-283
The pharmacokinetics and metabolism of tricyclic antidepressant drugs in patients with chronic renal failure....Pages 285-295
Factors affecting the biphasic concentration: effect relationships of tricyclic antidepressants....Pages 297-306
Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man....Pages 307-316
Front Matter....Pages 317-317
Cardiovascular effects of antidepressants....Pages 319-341
Cardiovascular effects of the tricyclic antidepressants: implications for new research....Pages 343-349
Antidepressant treatment with imipramine and nortriptyline in elderly patients....Pages 351-357
Neurological side effects and plasma and CSF levels....Pages 359-368
Clinical pharmacological approaches to evaluating tardive dyskinesia....Pages 369-383
Neuroleptic-induced ‘tardive Tourrette’s syndrome’ and neurotoxicity....Pages 385-387
Back Matter....Pages 389-409